Life science blog
  • Home
  • About
A Landmark Deal in Oncology: Pfizer's $6 Billion Bet on 3SBio's PD-1/VEGF Bispecific Antibody

A Landmark Deal in Oncology: Pfizer's $6 Billion Bet on 3SBio's PD-1/VEGF Bispecific Antibody

20 May 2025 2 min read Transaction
* In one of the most significant oncology licensing deals of 2025 to date, Pfizer has secured global rights (excluding mainland China) to 3SBio's promising PD-1/VEGF bispecific antibody, SSGJ-707, for a
Meetings & Willpower: Unveiling communication priorities  through Word Cloud analysis

Meetings & Willpower: Unveiling communication priorities through Word Cloud analysis

20 Apr 2025 1 min read Business Development
* I employed Word Cloud data visualization to analyze the most frequently used words in my email body over the past two years, aiming to uncover some intriguing trends. * Excluding common stop words and
Comparison of VS Code Remote SSH Port Forwarding Function and Reverse Proxy Server

Comparison of VS Code Remote SSH Port Forwarding Function and Reverse Proxy Server

29 Mar 2025 2 min read Home Lab
Feature/Comparison Dimension VS Code Remote SSH Port Forwarding Reverse Proxy Server Technical Implementation Connects local ports to remote server ports via an SSH tunnel, establishing an encrypted tunnel. The reverse proxy forwards
Novo Nodisk inks $200m upfront for UBT251 (GLP-1/GIP/Glucagon triple agonist) from United Lab (HKEX:03933)

Novo Nodisk inks $200m upfront for UBT251 (GLP-1/GIP/Glucagon triple agonist) from United Lab (HKEX:03933)

28 Mar 2025 2 min read Transaction
PUBLICATION_TIME(BEIJING): 2025-03-24 18:02:10 PROVIDER: Novo Nordisk A/S HEADLINE: The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist SUB_
FDA approved AMVUTTRA® (vutrisiran), the first RNAi therapeutic to reduce cardiovascular death, hospitalizations and urgent heart failure visits in adults with ATTR-CM

FDA approved AMVUTTRA® (vutrisiran), the first RNAi therapeutic to reduce cardiovascular death, hospitalizations and urgent heart failure visits in adults with ATTR-CM

28 Mar 2025 1 min read News
PUBLICATION_TIME(BEIJING): 2025-03-21 5:54:00 PROVIDER: Alnylam Pharmaceuticals, Inc. HEADLINE: Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits
Page 1 of 2
Next
Life science blog © 2025
Powered by Ghost